The riskbenefit assessment for wellness or anti-aging interventions may differ substantially from that applied to disease-specific therapeutic indications, given the differing clinical objectives and risk tolerances
Animal studies have confirmed that subcutaneous injection in one body area produces collagen synthesis improvements, enhanced angiogenesis, and accelerated wound closure at sites far from the injection point
The principal changes are as follows: GHK-Cu for non-injectable routes of administration is being removed from Category 1, and GHK-Cu for injectable routes of administration is separately being removed from Category 2
Peptide discussions should not replace diagnosis, rehabilitation, progressive strengthening, movement correction, imaging when needed, or appropriate medical care
Subcutaneous, in the abdomen